Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...
July 08, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...